EATRIS Developed Collaboration to Accelerate the Validation of New Thyroid Cancer Diagnostic
Rosetta Genomics Ltd announces the initiation by the EATRIS, of a new public-private translational research project between themselves and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool. The partnership was facilitated by EATRIS’ new business model that brings together private industry and academia, and is the result of a partnering meeting held at the BIO USA 2014 convention in San Diego, California.
Under this EATRIS private-public arrangement, the partners will work towards improving the diagnosis of malignant tumours in suspected thyroid cancer patients by connecting the expertise and clinical samples available at IMTM with the microRNA platform technology and product development expertise of Rosetta Genomics. “This partnership is a prime example of how EATRIS is paving the way to improved product development by facilitating collaborations that combine access to innovative translational research infrastructure and industry expertise. This is a great time to be part of EATRIS as patient outcomes are within reach,” noted Anton Ussi, Head of Operations at EATRIS.